NEW DELHI: Drug prices regulator, National Pharmaceutical Pricing Authority (NPPA), has called for strict monitoring of the implementation of trade margin rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified on Oct 17 with revised prices effective Nov 9.All manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been directed to comply with the revised prices and prominently display the updated price lists at their premises and websites, the authority said in an office memorandum issued earlier this week.The revised price lists, based on submissions received from companies up to Nov 11, are available on the NPPA website along with the ‘Pharma Sahi Daam’ app and portal.State drug controllers have been directed to strictly monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of revised MRPs are passed on to patients. Any violation may attract overcharging proceedings under the provisions of DPCO, 2013, NPPA said.
Complaints regarding overcharging, shortage or non-availability of medicines can be reported through the ‘Pharma Sahi Daam’ app/portal, NPPA helpline or email. Further, the state drug controllers have been asked to submit their action taken reports to NPPA by Nov 16.The move comes days after NPPA fixed 30% trade margins on 137 non-scheduled cancer drugs, translating to 1,391 brands and dosage forms. The list includes both patented and non-patented drugs based on a list recommended by an expert committee under Directorate General of Health Services (DGHS).